Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent pneumococcal conjugate vaccine (PCV13) was approved for protection against invasive disease and pneumonia caused by Streptococcus pneumoniae in adults. This study estima...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez González-Moro, Jose Miguel, Menéndez, Rosario, Campins, Magda, Lwoff, Nadia, Oyagüez, Itziar, Echave, María, Rejas, Javier, Antoñanzas, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706838/
https://www.ncbi.nlm.nih.gov/pubmed/26547199
http://dx.doi.org/10.1007/s40261-015-0345-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706838/
https://www.ncbi.nlm.nih.gov/pubmed/26547199
http://dx.doi.org/10.1007/s40261-015-0345-z

Ejemplares similares